已收盘 10-31 16:00:00 美东时间
-0.110
-0.64%
Cellebrite, a global leader in digital investigation and intelligence solutions, has appointed Holly Windham as General Counsel and Chief Compliance Officer. With extensive legal leadership experience in technology, cybersecurity, and data privacy, Windham will oversee all legal and compliance matters for the company, supporting its continued growth and market leadership. Her appointment follows Ayala Berler Shapira’s tenure. Windham previously s...
10-30 12:30
Terry Crews, known for hosting *America’s Got Talent* and his role on *Brooklyn 99*, will keynote Cellebrite’s C2C User Summit 2026. The event, held April 13-17, 2026, at the Washington, D.C. Marriott Marquis, will gather hundreds of professionals from the digital investigation and intelligence sectors. Crews, an advocate against human trafficking and sexual assault, will share personal experiences of overcoming adversity, inspiring attendees wit...
10-28 12:30
<p>Cellebrite (NASDAQ: CLBT), a leader in digital investigative solutions, announced it will release its third-quarter 2025 financial results after the U.S. market close on November 12, 2025. Later that day, the company will host a conference call and webcast at 5:00 p.m. ET to discuss the results and provide a full-year 2025 outlook. Details include a call-in number (203-518-9814 / 800-274-8461) with conference ID CLBTQ325, and webcast links ava...
10-17 13:00
Cellebrite的Autumn 2025 Release推出增强的数字调查平台,整合Corellium技术以提升移动设备和物联网分析能力。Guardian套件新增Investigate解决方案,利用AI统一证据,支持跨部门协作。新增对更多设备和版本的支持,以及AWS GovCloud部署选项,提升安全性和灵活性。Corellium解决方案为政府和企业提供全面的安全测试和漏洞研究,助力合规与风险控制。
10-15 12:30
今日重点评级关注:Ascendiant Capital:维持Maison Solutions"买入"评级,目标价从4美元升至4.25美元;瑞穗:维持MBX Biosciences"跑赢大市"评级,目标价从38美元升至56美元
09-25 09:52
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and raises the price target from $20 to $23.
09-24 20:30
今日重点评级关注:Northland Capital Markets:维持BrainsWay"跑赢大市"评级,目标价从15美元升至19美元;Lake Street:维持Hyperfine"买入"评级,目标价从1.5美元升至2美元
08-15 09:30
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to $18.
08-15 01:44
Cellebrite shares are trading higher after the company reported better-than-exp...
08-14 22:10
Cellebrite DI (NASDAQ:CLBT) sees Q3 sales of $121.000 million-$126.000 million vs $124.357 million analyst estimate.
08-14 19:03